Cargando…

2948. Pediatric Clinical Outcomes of MRSA PCR Utilization for Anti-MRSA De-escalation

BACKGROUND: Methicillin resistant Staphylococcus aureus (MRSA) remains a major infectious disease challenge often requiring empiric therapy. Rapid identification methods, such as MRSA polymerase chain reaction (MRSA PCR) have been increasingly utilized as a stewardship tool for antimicrobial de-esca...

Descripción completa

Detalles Bibliográficos
Autores principales: Demirhan, Salih, Escobar Lee, Kiriam, Lee, Philip J, Sy, Sharlene, Anosike, Brenda I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677534/
http://dx.doi.org/10.1093/ofid/ofad500.187
_version_ 1785150152584986624
author Demirhan, Salih
Escobar Lee, Kiriam
Lee, Philip J
Sy, Sharlene
Anosike, Brenda I
author_facet Demirhan, Salih
Escobar Lee, Kiriam
Lee, Philip J
Sy, Sharlene
Anosike, Brenda I
author_sort Demirhan, Salih
collection PubMed
description BACKGROUND: Methicillin resistant Staphylococcus aureus (MRSA) remains a major infectious disease challenge often requiring empiric therapy. Rapid identification methods, such as MRSA polymerase chain reaction (MRSA PCR) have been increasingly utilized as a stewardship tool for antimicrobial de-escalation in adults. More recently, a growing, albeit small, number of pediatric studies have demonstrated similar promise. However, there remains a paucity of data evaluating clinical outcomes of using MRSA PCR as a stewardship tool in pediatrics. METHODS: Retrospective cohort study of nasal MRSA PCRs collected from hospitalized patients ≤ 21 years of age between November 1, 2021, and February 28, 2023. Indications for testing were categorized into 4 clinical syndromes defined a priori: pneumonia; skin and soft tissue infections (SSTI); head and neck infections (HNI); and bacteremia. Each MRSA PCR test was counted per single episode. Inclusion: all those who started on an anti-MRSA agent and discontinued ≤48 hours of a negative PCR. Primary endpoint: any adverse clinical outcome defined as restarting an anti-MRSA agent in 7 days (14 days for SSTI), readmission for same indication in 30 days, escalation of ventilatory support, new inotropic support and/or transfer to intensive care unit (ICU) -all in 7 days; and in-house mortality in 30 days. [Figure: see text] RESULTS: Total of 145 patients with 156 episodes met inclusion criteria; demographic and clinical characteristics are shown in Table 1. Pneumonia (39.1%) and SSTI (24.4%) were the most common indications for testing. 58.3%) were in the ICU at the time of testing; 48.7% received respiratory support. Vancomycin (57.0%) was the most used antibiotic. Clinical characteristics of episodes are shown in Table 2. Fifteen patients (9.6%) had any of the adverse outcomes (negative predictive value =90.4%, [95%CI: 84.6-94.5]); only 3 were restarted on an anti-MRSA agent (Table 3). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: In this single center study of pediatric patients who had a negative MRSA PCR nasal swab, none grew MRSA from cultures. Though limited, early discontinuation of anti-MRSA antibiotics was not associated with high rates of any adverse outcome suggesting the role of MRSA PCRs as a useful clinical stewardship tool in children. Larger/prospective studies are still needed. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677534
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106775342023-11-27 2948. Pediatric Clinical Outcomes of MRSA PCR Utilization for Anti-MRSA De-escalation Demirhan, Salih Escobar Lee, Kiriam Lee, Philip J Sy, Sharlene Anosike, Brenda I Open Forum Infect Dis Abstract BACKGROUND: Methicillin resistant Staphylococcus aureus (MRSA) remains a major infectious disease challenge often requiring empiric therapy. Rapid identification methods, such as MRSA polymerase chain reaction (MRSA PCR) have been increasingly utilized as a stewardship tool for antimicrobial de-escalation in adults. More recently, a growing, albeit small, number of pediatric studies have demonstrated similar promise. However, there remains a paucity of data evaluating clinical outcomes of using MRSA PCR as a stewardship tool in pediatrics. METHODS: Retrospective cohort study of nasal MRSA PCRs collected from hospitalized patients ≤ 21 years of age between November 1, 2021, and February 28, 2023. Indications for testing were categorized into 4 clinical syndromes defined a priori: pneumonia; skin and soft tissue infections (SSTI); head and neck infections (HNI); and bacteremia. Each MRSA PCR test was counted per single episode. Inclusion: all those who started on an anti-MRSA agent and discontinued ≤48 hours of a negative PCR. Primary endpoint: any adverse clinical outcome defined as restarting an anti-MRSA agent in 7 days (14 days for SSTI), readmission for same indication in 30 days, escalation of ventilatory support, new inotropic support and/or transfer to intensive care unit (ICU) -all in 7 days; and in-house mortality in 30 days. [Figure: see text] RESULTS: Total of 145 patients with 156 episodes met inclusion criteria; demographic and clinical characteristics are shown in Table 1. Pneumonia (39.1%) and SSTI (24.4%) were the most common indications for testing. 58.3%) were in the ICU at the time of testing; 48.7% received respiratory support. Vancomycin (57.0%) was the most used antibiotic. Clinical characteristics of episodes are shown in Table 2. Fifteen patients (9.6%) had any of the adverse outcomes (negative predictive value =90.4%, [95%CI: 84.6-94.5]); only 3 were restarted on an anti-MRSA agent (Table 3). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: In this single center study of pediatric patients who had a negative MRSA PCR nasal swab, none grew MRSA from cultures. Though limited, early discontinuation of anti-MRSA antibiotics was not associated with high rates of any adverse outcome suggesting the role of MRSA PCRs as a useful clinical stewardship tool in children. Larger/prospective studies are still needed. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677534/ http://dx.doi.org/10.1093/ofid/ofad500.187 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Demirhan, Salih
Escobar Lee, Kiriam
Lee, Philip J
Sy, Sharlene
Anosike, Brenda I
2948. Pediatric Clinical Outcomes of MRSA PCR Utilization for Anti-MRSA De-escalation
title 2948. Pediatric Clinical Outcomes of MRSA PCR Utilization for Anti-MRSA De-escalation
title_full 2948. Pediatric Clinical Outcomes of MRSA PCR Utilization for Anti-MRSA De-escalation
title_fullStr 2948. Pediatric Clinical Outcomes of MRSA PCR Utilization for Anti-MRSA De-escalation
title_full_unstemmed 2948. Pediatric Clinical Outcomes of MRSA PCR Utilization for Anti-MRSA De-escalation
title_short 2948. Pediatric Clinical Outcomes of MRSA PCR Utilization for Anti-MRSA De-escalation
title_sort 2948. pediatric clinical outcomes of mrsa pcr utilization for anti-mrsa de-escalation
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677534/
http://dx.doi.org/10.1093/ofid/ofad500.187
work_keys_str_mv AT demirhansalih 2948pediatricclinicaloutcomesofmrsapcrutilizationforantimrsadeescalation
AT escobarleekiriam 2948pediatricclinicaloutcomesofmrsapcrutilizationforantimrsadeescalation
AT leephilipj 2948pediatricclinicaloutcomesofmrsapcrutilizationforantimrsadeescalation
AT sysharlene 2948pediatricclinicaloutcomesofmrsapcrutilizationforantimrsadeescalation
AT anosikebrendai 2948pediatricclinicaloutcomesofmrsapcrutilizationforantimrsadeescalation